Wire · opportunities
FDA Clears C2N Diagnostics' PrecivityAD2® — First Alzheimer's Blood Test for Adults with ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 August 2026 · Fusion42 review
The FDA has cleared C2N Diagnostics' PrecivityAD2®, the first blood test approved for aiding diagnosis of Alzheimer’s disease in adults aged 40 and over with cognitive symptoms. The test offers a less invasive, scalable option to help health care professionals identify amyloid pathology associated with Alzheimer’s, complementing clinical assessment and potentially accelerating treatment decisions.
This Wire brief sits within Fusion42's coverage of Digital Health, and 4 sources have reported it between 20 Aug 2026 and 21 Aug 2026.
◆ ◆ The Wire takeaway
You gain a new tool proven to speed up Alzheimer’s diagnosis in symptomatic adults from age 40. Early detection routes just opened wider, letting you reach patients before disease advances.
◆ Coverage
4 sources · first reported 20 Aug 2026 · latest 21 Aug 2026
◆ Related on Wire
◆ Topics